SCHEMBL15351997

SCHEMBL15351997

Sc1cc(Cl)c2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 7/20 0.50
▸ CYP1A2 P05177 5/20 0.50
▸ ALDH1A1 P00352 4/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ CYP1B1 Q16678 1/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ MAPT P10636 2/20 0.39
▸ CCR1 P32246 1/20 0.38
▸ CCR8 P51685 1/20 0.38
▸ TRPM4 Q8TD43 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ HTR2A P28223 1/20 0.35
▸ NQO2 P16083 1/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ TDP2 O95551 1/20 0.35
▸ CDC25B P30305 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5024019 0.76 CYP2A6 (0.54) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL6007540 0.76 ALDH1A1 (0.44) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL30366335 0.76 CYP2A6 (0.54) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL11617238 0.76 CYP1A2 (0.54) CYP2A6CYP1A2ALDH1A1TSHRMEN1
SCHEMBL690094 0.74 ALDH1A1 (0.52) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL9730016 0.74 CYP2A6 (0.52) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL31157796 0.74 ALDH1A1 (0.52) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL1922076 0.73 ALDH1A1 (0.55) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL30494614 0.73 ALDH1A1 (0.55) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A
SCHEMBL24362131 0.73 CYP2A6 (0.50) CYP2A6CYP1A2ALDH1A1HSD17B10HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2841429-B1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2020-10-21 — — EP disclosed
EP-2841433-B1 TETRAZOLINONE COMPOUNDS AND ITS USE SUMITOMO CHEMICAL CO (JP) 2017-06-21 — — EP disclosed
US-9565856-B2 Tetrazolinone compounds and its use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-14 — — US disclosed
US-9380782-B2 Tetrazolinone compounds and its use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-07-05 — — US disclosed
EP-2841429-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES Sumitomo Chemical Company Limited (JP) 2015-03-04 — — EP disclosed
EP-2841433-A1 TETRAZOLINONE COMPOUNDS AND ITS USE Sumitomo Chemical Company Limited (JP) 2015-03-04 — — EP disclosed
US-20150051171-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-02-19 — — US disclosed
US-20150031733-A1 TETRAZOLINONE COMPOUNDS AND ITS USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-01-29 — — US disclosed
WO-2013162072-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-10-31 — — WO disclosed
WO-2013162077-A1 TETRAZOLINONE COMPOUNDS AND ITS USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031733-A1 TETRAZOLINONE COMPOUNDS AND ITS USE CBR3, CYP51A1, CYP8B1 CYP2A6 127/4885CYP1A2 18/4885ALDH1A1 1716/4885
US-20150051171-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES CBR3, CYCS, CBR1 CYP2A6 100/4885CYP1A2 49/4885ALDH1A1 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback